OBJECTIVE:To explore the effectiveness and safety of bicyclol combined with ganciclovir in the treatment of infan-tile cytomegaloirus hepatitis. METHODS:One hundred and twenty children with cytomegaloirus hepatitis in department of pediatrics of our hospital during May 2012-Aug. 2015 were selected and divided into observation group and control group according to random number table,with 60 cases in each group. Both groups received conventional treatment such as protecting liver,vitamin C,vitamin K and Compound glycyrrhizin injection 20 mL,ivgtt,qd. Control group additionally received Ganciclovir injection(induction period:5 mg/kg,q12 h,dripping time >1 h,for 7 d;maintenance period:5 mg/kg,q24 h,for 7 d);observation group was additionally giv-en Bicyclol tablet 0.5 mg/kg,bid,on the basis of control group. Clinical efficacies of 2 groups were observed as well as liver enzyme level,jaundice level before and after treatment. The rate of negative CMV and the occurrence of ADR were compared. RESULTS:Clinical total response rate of observation group was 93.3%,which was significantly higher than 80.0% of control group,with statisti-cal significance(P<0.05). There was no statistical significance in liver enzyme level and jaundice level between 2 groups before treat-ment(P>0.05). After treatment,liver enzyme level and jaundice level of 2 groups were decreased significantly,and observation group was significantly lower than control group,with statistical significance(P<0.05). The rate of total negative CMV in observa-tion group was 85.0%,which was significantly higher than 73.3% of control group,with statistical significance(P<0.05). There was no statistical significance in the incidence of ADR between 2 groups(P>0.05). CONCLUSIONS:Bicyclol combined with ganci-clovir shows significant therapeutic efficacy for infantile cytomegaloirus hepatitis,and can effectively reduce the levels of liver en-zymes,eliminate jaundice,protect liver function,promote virus clearance with good safety.

Objective To investigate the mucosal immunity of L1 virus-like particles ( VLPs) of human papillomavirus ( HPV) types 16 and 18 plus JY adjuvant by intranasal immunization in cynomolgus. Methods Cynomolgus were immunized with low and high dosage of HPV types 16 and 18 L1 VLP with JY adjuvant for 3 times by intranasal route at weeks 0, 4 and 8, respectively, using PBS as control. Subsequently, vaginal secretion, oral secretion and nasal secretion were collected at weeks 0, 2, 4, 6, 8 and 16, respectively, and determined for mucosal immunity by ELISA.Results HPV-L1-specific sIgA antibodies were detected in all secretions, including oral, nasal and vaginal ones, the concentrations of sIgA antibody induced were much higher than those in PBS control group.There was no significant difference ( P>0.05) in sIgA antibody levels among cynomolgus vaccinated with low and high dosage of L1 VLP, as was between oral and nasal secretion ( P >0.05 ) , However, the concentrations of sIgA antibody in vaginal secretion were significant higher than those in oral and nasal secretion, differences were statistically significant ( P<0.01) .Conclusions Following intranasal immunization in cynomolgus, HPV types 16 and 18 L1 VLP with JY adjuvant can effectively induce sIgA antibody in vaginal secretion, and vaginal sIgA antibody concentrations were much higher than those in oral and nasal secretion.